ES2175663T3 - Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis. - Google Patents

Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.

Info

Publication number
ES2175663T3
ES2175663T3 ES98904121T ES98904121T ES2175663T3 ES 2175663 T3 ES2175663 T3 ES 2175663T3 ES 98904121 T ES98904121 T ES 98904121T ES 98904121 T ES98904121 T ES 98904121T ES 2175663 T3 ES2175663 T3 ES 2175663T3
Authority
ES
Spain
Prior art keywords
treatment
oral administration
miltephosine
leshmaniasis
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98904121T
Other languages
English (en)
Inventor
Jurgen Engel
Werner Sarlikiotis
Thomas Klenner
Peter Hilgard
Dieter Sauerbier
Eckhard Milsmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Application granted granted Critical
Publication of ES2175663T3 publication Critical patent/ES2175663T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Utilización de miltefosina para la preparación de un medicamento para el tratamiento de la leishmaniasis en la especie humana por administración oral, por la que se administra oralmente una dosis diaria total en el intervalo de 10 a 250 mg del i.a. (ingrediente activo) miltefosina durante un período de tiempo de 2 a 6 semanas.
ES98904121T 1998-01-22 1998-01-22 Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis. Expired - Lifetime ES2175663T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/000345 WO1999037289A1 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Publications (1)

Publication Number Publication Date
ES2175663T3 true ES2175663T3 (es) 2002-11-16

Family

ID=8166843

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98904121T Expired - Lifetime ES2175663T3 (es) 1998-01-22 1998-01-22 Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.

Country Status (24)

Country Link
US (1) US6544551B1 (es)
EP (1) EP1051159B1 (es)
JP (1) JP2002501015A (es)
KR (1) KR100517399B1 (es)
CN (1) CN100413492C (es)
AT (1) ATE215817T1 (es)
AU (1) AU756805B2 (es)
BR (1) BR9814772A (es)
CA (1) CA2318260C (es)
CZ (1) CZ299229B6 (es)
DE (1) DE69804865T2 (es)
DK (1) DK1051159T3 (es)
ES (1) ES2175663T3 (es)
HU (1) HUP0004363A3 (es)
IL (1) IL136196A (es)
NO (1) NO20003674L (es)
NZ (1) NZ505648A (es)
PL (1) PL189654B1 (es)
PT (1) PT1051159E (es)
SI (1) SI1051159T1 (es)
SK (1) SK284839B6 (es)
TR (1) TR200001717T2 (es)
UA (1) UA68372C2 (es)
WO (1) WO1999037289A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
WO2003090757A1 (en) * 2002-04-26 2003-11-06 Rudolf Perl Pharmaceutical compositions of phospholipid derivatives
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
KR20130016413A (ko) 2002-07-30 2013-02-14 아에테르나 젠타리스 게엠베하 항종양 약제와 조합하여 사용하기 위한 알킬포스포콜린의 약물 제품
CA2526586C (en) 2003-09-09 2010-03-16 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
EP1799196B1 (en) 2004-10-08 2016-06-22 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
MX2011011596A (es) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.
MX2013005687A (es) 2010-11-22 2013-10-17 Dafra Pharma Res & Dev Bvba Formas de dosificación sólida de oleil fosfocolina.
EP2723347B1 (en) 2011-06-24 2019-09-04 GRI Bio, Inc. Prevention and treatment of inflammatory conditions
JP2016515602A (ja) * 2013-04-08 2016-05-30 アカデミッシュ メディッシュ セントラム Ｉｂｄの治療に使用するためのミルテホシンまたはペリホシン
KR102193599B1 (ko) 2014-09-17 2020-12-21 스티어라이프 인디아 프라이빗 리미티드 발포성 조성물 및 이의 제조방법
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法
WO2017098481A1 (en) 2015-12-12 2017-06-15 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
EP3965739B1 (en) * 2019-04-12 2024-07-10 Oblita Therapeutics BVBA Tablet dosage formulations of oleyl phosphocholine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (de) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Verfahren zum Tablettieren von hygroskopischen Praeparaten
CA1338627C (en) * 1985-12-04 1996-10-01 Hansjorg Eibl Pharmaceuticals based on phosphoric acid esters for use in tumor therapy, and process for their preparation
US4762658A (en) * 1986-10-08 1988-08-09 Central Soya Company, Inc. Method of tableting of de-oiled phosphatides (lecithin)
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
EP0419998A3 (en) * 1989-09-27 1991-10-23 Asta Pharma Aktiengesellschaft Use of alkylphosphonic acid derivatives for the treatment of psoriasis
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis

Also Published As

Publication number Publication date
TR200001717T2 (tr) 2000-11-21
IL136196A0 (en) 2001-05-20
SK284839B6 (sk) 2005-12-01
NO20003674D0 (no) 2000-07-18
BR9814772A (pt) 2000-10-24
PL189654B1 (pl) 2005-09-30
KR20010034311A (ko) 2001-04-25
AU6212198A (en) 1999-08-09
DK1051159T3 (da) 2002-08-05
KR100517399B1 (ko) 2005-09-28
CA2318260C (en) 2006-11-21
HUP0004363A2 (hu) 2001-04-28
CA2318260A1 (en) 1999-07-29
CZ20002596A3 (cs) 2000-10-11
CN1283111A (zh) 2001-02-07
NZ505648A (en) 2002-10-25
SI1051159T1 (en) 2002-10-31
IL136196A (en) 2004-07-25
PL342838A1 (en) 2001-07-16
DE69804865T2 (de) 2002-11-07
EP1051159A1 (en) 2000-11-15
HUP0004363A3 (en) 2002-12-28
NO20003674L (no) 2000-07-18
SK9862000A3 (en) 2000-11-07
DE69804865D1 (de) 2002-05-16
JP2002501015A (ja) 2002-01-15
AU756805B2 (en) 2003-01-23
WO1999037289A1 (en) 1999-07-29
CN100413492C (zh) 2008-08-27
EP1051159B1 (en) 2002-04-10
PT1051159E (pt) 2002-09-30
US6544551B1 (en) 2003-04-08
ATE215817T1 (de) 2002-04-15
CZ299229B6 (cs) 2008-05-21
UA68372C2 (en) 2004-08-16

Similar Documents

Publication Publication Date Title
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
BR0015188A (pt) Composições farmacêuticas
MX9700081A (es) Composiciones farmaceuticas de tacrina.
KR960700708A (ko) 3,4-디아릴크로만을 이용한 뼈 손실의 억제방법(methdos for inhibiting bone loss with 3,4-diarylchroman)
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
CZ289643B6 (cs) Lék pro léčbu bolesti v krku obsahující flurbiprofen
EP1444984B1 (en) Topical pharmaceutical compositions containing natural active constituents suitable for the prevention and treatment of mucosal inflammation processes
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
NO20055880L (no) Memantin orale doseringsformer
SE9901573D0 (sv) New compounds
BR0114100A (pt) Formulações de liberação controlada para administração oral
ES2171440T3 (es) Composicion solida mucoadhesiva, terapeutica o higienica, para administracion por aplicacion sobre la mucosa bucal o nasal.
KR970025615A (ko) 암 전이 억제제
CO5580741A2 (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1
RU2010109359A (ru) Азитромицин для лечения кожных заболеваний
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
MXPA03003994A (es) Composiciones de metformina de liberacion controlada.
BR0014593A (pt) Unidade de dosagem para administração peroral
ES2078838A1 (es) Procedimiento para preparar una composicion a base de clozapina.
AR042153A1 (es) Uso de los compuestos 2,5- dihidroxibencenosulfonicos para la fabricacion de un medicamento
AR030551A1 (es) Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1051159

Country of ref document: ES